We are live on ! Find out more

1,001 hedge funds and large institutions have $24.6B invested in Biogen in 2025 Q4 according to their latest regulatory filings, with 190 funds opening new positions, 323 increasing their positions, 296 reducing their positions, and 81 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more funds holding in top 10

Funds holding in top 10: 38 (+5)

135% more first-time investments, than exits

New positions opened: 190 | Existing positions closed: 81

58% more call options, than puts

Call options by funds: $715M | Put options by funds: $454M

33% more capital invested

Capital invested by funds: $18.5B → $24.6B (+$6.12B)

10% more funds holding

Funds holding: 9081,001 (+93)

5.68% more ownership

Funds ownership: 89.57%95.25% (+5.7%)

9% more repeat investments, than reductions

Existing positions increased: 323 | Existing positions reduced: 296

Holders
1,001
Holders Change
+93
Holders Change %
+10.24%
% of All Funds
12.11%
Holding in Top 10
8
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+166.67%
% of All Funds
0.1%
New
190
Increased
323
Reduced
296
Closed
81
Calls
$715M
Puts
$454M
Net Calls
+$262M
Net Calls Change
+$4.73M

BIIB Hedge Fund Activity: Q4 2025 in Review

1,001 of the 8,264 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q4 2025, worth a combined $24.6B — up 33% from $18.5B a quarter earlier.

Buyers outnumbered sellers: 190 funds opened new BIIB positions and 81 closed out — a net gain of 109 holders — while 323 added to existing stakes and 296 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $1.33B. The largest seller was Point72 Asset Management, cutting an estimated $173M.

  • 1,001 institutional investors held Biogen (BIIB) as of Q4 2025, up from 908 in Q3 2025.
  • Funds reported $24.6B of Biogen stock for Q4 2025, up 33% quarter-over-quarter.
  • 190 funds opened new Biogen positions in Q4 2025 and 81 closed out, a net change of +109 holders.
  • The largest Biogen buyer in Q4 2025 was Fidelity Investments, an estimated $1.33B added.
  • The largest Biogen seller in Q4 2025 was Point72 Asset Management, an estimated $173M sold.

Based on aggregated 13F filings for Q4 2025.